Aducanumab Panel Pushes Back On Rosy FDA Outlook, Could Derail A Swift Approval

 
• By Jessica Merrill
Freight train accident
FDA's aducanumab advisory committee meeting puts the review off track • Source: Shutterstock

More from Neurological

More from Therapeutic Category